As of 2025-10-17, the Relative Valuation of Kymera Therapeutics Inc (KYMR) is (51.81) USD. This relative valuation is based on P/E multiples. With the latest stock price at 60.46 USD, the upside of Kymera Therapeutics Inc based on Relative Valuation is -185.7%.
The range of the Relative Valuation is (41.60) - (60.17) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.8x - 15.6x | 13.5x |
| Forward P/E multiples | 10.7x - 17.1x | 13.4x |
| Fair Price | (41.60) - (60.17) | (51.81) |
| Upside | -168.8% - -199.5% | -185.7% |
| Date | P/E |
| 2025-10-16 | -15.69 |
| 2025-10-15 | -16.33 |
| 2025-10-14 | -15.12 |
| 2025-10-13 | -15.55 |
| 2025-10-10 | -14.85 |
| 2025-10-09 | -14.80 |
| 2025-10-08 | -14.61 |
| 2025-10-07 | -14.78 |
| 2025-10-06 | -14.94 |
| 2025-10-03 | -15.03 |
| 2025-10-02 | -14.54 |
| 2025-10-01 | -14.19 |
| 2025-09-30 | -14.69 |
| 2025-09-29 | -15.19 |
| 2025-09-26 | -14.60 |
| 2025-09-25 | -13.95 |
| 2025-09-24 | -13.63 |
| 2025-09-23 | -13.21 |
| 2025-09-22 | -13.24 |
| 2025-09-19 | -12.75 |
| 2025-09-18 | -13.28 |
| 2025-09-17 | -12.49 |
| 2025-09-16 | -12.66 |
| 2025-09-15 | -12.27 |
| 2025-09-12 | -12.20 |
| 2025-09-11 | -11.99 |
| 2025-09-10 | -11.29 |
| 2025-09-09 | -11.29 |
| 2025-09-08 | -11.23 |
| 2025-09-05 | -11.29 |
| 2025-09-04 | -10.95 |
| 2025-09-03 | -11.24 |
| 2025-09-02 | -10.56 |
| 2025-08-29 | -10.70 |
| 2025-08-28 | -10.84 |
| 2025-08-27 | -10.97 |
| 2025-08-26 | -11.39 |
| 2025-08-25 | -10.86 |
| 2025-08-22 | -11.45 |
| 2025-08-21 | -11.06 |
| 2025-08-20 | -10.99 |
| 2025-08-19 | -11.05 |
| 2025-08-18 | -11.32 |
| 2025-08-15 | -11.07 |
| 2025-08-14 | -10.79 |
| 2025-08-13 | -10.57 |
| 2025-08-12 | -10.35 |
| 2025-08-11 | -9.78 |
| 2025-08-08 | -10.54 |
| 2025-08-07 | -10.60 |